The Scottish Medicines Consortium (SMC) has announced that Saflutan (tafluprost) has been accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension
7 December 2009, Hoddesdon – The Scottish Medicines Consortium (SMC) has announced that Saflutan (tafluprost) has been accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension - as monotherapy (in patients who would benefit from preservative-free eye-drops, who are insufficiently responsive to first-line therapy, or who are intolerant or contraindicated to first-line therapy) or as adjunctive therapy to beta blockers. It is restricted to use in patients who cannot tolerate the currently available prostaglandin preparations due to proven sensitivity to the preservative benzalkonium chloride.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials